Investig Clin Urol.  2020 Mar;61(2):231-237. 10.4111/icu.2020.61.2.231.

Sleep disturbance changes in women after treatment of refractory overactive bladder with sacral neuromodulation

Affiliations
  • 1Department of Obstetrics and Gynecology, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA. derrick_sanderson@urmc.rochester.edu
  • 2University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.
  • 3Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.

Abstract

PURPOSE
The aim of this study is to evaluate changes in sleep disturbance following treatment of overactive bladder with sacral neuromodulation.
MATERIALS AND METHODS
This is a sub-analysis of data collected from an institutional review board approved retrospective cohort study evaluating women with Patient-Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) before and after sacral neuromodulation for overactive bladder between March 2016 and October 2017. Data collected included demographics, clinical characteristics, and additional PROMIS item banks. Within-group analysis was performed with paired t-tests. Groups based up on PROMIS-SD improvement (change <0) were then compared using Fisher's exact test, t-test, or Mann-Whitney U-test as appropriate.
RESULTS
Those with improved sleep disturbance (n=7) noted a significant mean improvement of −3.99 (95% confidence interval, −6.32, −1.65; p<0.01). Both pre- and post-procedure PROMIS-Physical Function (38.86±2.35 vs. 34.13±5.58, p=0.07 and 37.14±5.10 vs. 35.44±4.74, p=0.53), Pain Interference (60.04±6.34 vs. 65.50±6.20, p=0.13 and 57.89±5.08 vs. 64.73±7.35, p=0.07), Depression (44.2±4.73 vs. 61.29±9.53, p=0.17 and 54.29±6.25 vs. 57.96±11.42, p=0.47) t-scores were similar between sleep response groups.
CONCLUSIONS
Those with improved sleep disturbance reported significant changes after sacral neuromodulation for overactive bladder. However, no significant differences were identified between those with and without improvement. Further investigation of changes in sleep disturbance and factors affecting change are needed within this population.

Keyword

Implantable neurostimulators; Patient reported outcome measures; Sleep; Urinary bladder, overactive; Urinary incontinence

MeSH Terms

Cohort Studies
Demography
Depression
Ethics Committees, Research
Female
Humans
Implantable Neurostimulators
Retrospective Studies
Urinary Bladder, Overactive*
Urinary Incontinence

Reference

1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29:4–20.
Article
2. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001; 76:358–363.
Article
3. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20:327–336.
Article
4. Winkelman WD, Warsi A, Huang AJ, Schembri M, Rogers RG, Richter HE, et al. Sleep quality and daytime sleepiness among women with urgency predominant urinary incontinence. Female Pelvic Med Reconstr Surg. 2018; 24:76–81.
Article
5. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013; 67:1015–1033.
Article
6. Melotti IGR, Juliato CRT, Tanaka M, Riccetto CLZ. Severe depression and anxiety in women with overactive bladder. Neurourol Urodyn. 2018; 37:223–228.
Article
7. Grandner MA, Jackson NJ, Pak VM, Gehrman PR. Sleep disturbance is associated with cardiovascular and metabolic disorders. J Sleep Res. 2012; 21:427–433.
Article
8. Ge TJ, Vetter J, Lai HH. Sleep disturbance and fatigue are associated with more severe urinary incontinence and overactive bladder symptoms. Urology. 2017; 109:67–73.
Article
9. Warsi QA, Huang AJ, Hess R, Arya LA, Richter HE, Bradley CS, et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstet Gynecol. 2018; 131:204–211.
Article
10. Takao T, Tsujimura A, Yamamoto K, Fukuhara S, Nakayama J, Matsuoka Y, et al. Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance. Urology. 2011; 78:648–652.
Article
11. Powell CR, Zabell JR, Takacs EB, Kreder KJ. Reduction of nocturia after sacral neuromodulation therapy for overactive bladder. J Urol Res. 2015; 2:4.
12. Jairam R, Drossaerts J, Vrijens D, Leue C, van Kerrebroeck P, van Koeveringe G. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: a prospective follow-up study. Neurourol Urodyn. 2018; 37:1801–1808.
Article
13. Noblett K, Mangel J, Comiter C, Bird E, Griebling TL, Sutherland SE. MP77-15 quality of life after sacral neuromodulation: does it differ in subjects across different overactive bladder diagnoses? J Urol. 2016; 195(4S):e1021.
Article
14. Shaker HS, Hassouna M. Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence. J Urol. 1998; 159:1516–1519.
Article
15. Hassouna MM, Siegel SW, Nÿeholt AA, Elhilali MM, van Kerrebroeck PE, Das AK, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000; 163:1849–1854.
Article
16. Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015; 34:224–230.
Article
17. Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers-are we doing enough? J Urol. 2018; 199:779–784.
Article
18. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. PROMIS Cooperative Group. The patient-reported outcomes measurement information system (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007; 45:5 Suppl 1. S3–S11.
19. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. PROMIS Cooperative Group. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010; 63:1179–1194.
Article
20. Cappelleri JC, Jason Lundy J, Hays RD. Overview of classical test theory and item response theory for the quantitative assessment of items in developing patient-reported outcomes measures. Clin Ther. 2014; 36:648–662.
Article
21. Sung VW, Marques F, Rogers RR, Williams DA, Myers DL, Clark MA. Content validation of the patient-reported outcomes measurement information system (PROMIS) framework in women with urinary incontinence. Neurourol Urodyn. 2011; 30:503–509.
Article
22. Sung VW, Griffith JW, Rogers RG, Raker CA, Clark MA. Item bank development, calibration and validation for patient-reported outcomes in female urinary incontinence. Qual Life Res. 2016; 25:1645–1654.
Article
23. Siddiqui NY, Wiseman JB, Cella D, Bradley CS, Lai HH, Helmuth ME, et al. LURN. Mental health, sleep and physical function in treatment seeking women with urinary incontinence. J Urol. 2018; 200:848–855.
Article
24. Bass M, Morris S, Neapolitan R. Utilizing multidimensional computer adaptive testing to mitigate burden with patient reported outcomes. AMIA Annu Symp Proc. 2015; 2015:320–328.
25. Fries JF, Krishnan E, Rose M, Lingala B, Bruce B. Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory. Arthritis Res Ther. 2011; 13:R147.
Article
26. Liu H, Cella D, Gershon R, Shen J, Morales LS, Riley W, et al. Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. J Clin Epidemiol. 2010; 63:1169–1178.
Article
27. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41:582–592.
28. Gorter R, Fox JP, Twisk JW. Why item response theory should be used for longitudinal questionnaire data analysis in medical research. BMC Med Res Methodol. 2015; 15:55.
Article
29. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002; 11:563–574.
30. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis. 2013; 10:E65.
Article
Full Text Links
  • ICU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr